Sex Differences in Biopsy-Confirmed Diabetic Kidney Disease.
diabetic kidney disease
end stage kidney disease
risk factors
sex differences
type 2 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
02
2021
accepted:
05
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
21
12
2021
Statut:
epublish
Résumé
To investigate the association between sex differences and end-stage kidney disease (ESKD) in patients with biopsy-confirmed diabetic kidney disease (DKD). We performed a retrospective cohort study. A total of 336 patients with biopsy-confirmed DKD who were followed up for at least 12 months were enrolled. Baseline clinical and pathological data at the time of biopsy were collected. ESKD was defined by an estimated glomerular filtration rate of <15 ml/min/1.73 m There were 239 (71%) male and 97 (29%) female patients in our cohort. Female patients had higher systolic blood pressure, total cholesterol and low-density lipoprotein cholesterol levels compared with male. There were a lower proportion of female patients in the very high risk grade according to the chronic kidney disease categories (37% of female vs. 44% of male). During a median follow-up time of 20 months, 101 (57.7%) male and 43 (44.3%) female entered into ESKD, with no significant difference by the log-rank test ( Female patients had the higher systolic blood pressure, total cholesterol, LDL-C, compared with male patients. However, there was no significant association observed between sex difference and ESKD in our study.
Sections du résumé
Background
To investigate the association between sex differences and end-stage kidney disease (ESKD) in patients with biopsy-confirmed diabetic kidney disease (DKD).
Method
We performed a retrospective cohort study. A total of 336 patients with biopsy-confirmed DKD who were followed up for at least 12 months were enrolled. Baseline clinical and pathological data at the time of biopsy were collected. ESKD was defined by an estimated glomerular filtration rate of <15 ml/min/1.73 m
Result
There were 239 (71%) male and 97 (29%) female patients in our cohort. Female patients had higher systolic blood pressure, total cholesterol and low-density lipoprotein cholesterol levels compared with male. There were a lower proportion of female patients in the very high risk grade according to the chronic kidney disease categories (37% of female vs. 44% of male). During a median follow-up time of 20 months, 101 (57.7%) male and 43 (44.3%) female entered into ESKD, with no significant difference by the log-rank test (
Conclusion
Female patients had the higher systolic blood pressure, total cholesterol, LDL-C, compared with male patients. However, there was no significant association observed between sex difference and ESKD in our study.
Identifiants
pubmed: 34393995
doi: 10.3389/fendo.2021.670674
pmc: PMC8360678
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
670674Informations de copyright
Copyright © 2021 Wang, Zhang, Zhang, Wu, Zhang, Ren, Cooper and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Med. 2004 Feb 15;116(4):263-72
pubmed: 14969655
Curr Diab Rep. 2004 Dec;4(6):455-61
pubmed: 15539011
JAMA. 2003 Oct 8;290(14):1884-90
pubmed: 14532317
Mayo Clin Proc. 2020 Mar;95(3):587-599
pubmed: 32138885
J Am Soc Nephrol. 2019 Jan;30(1):137-146
pubmed: 30510134
J Nucl Cardiol. 2017 Aug;24(4):1226-1235
pubmed: 27048307
Am J Physiol Cell Physiol. 2012 Apr 15;302(8):C1174-88
pubmed: 22262063
Am J Kidney Dis. 2018 Jan;71(1):65-74
pubmed: 29157731
Nephrol Dial Transplant. 1998 Jun;13(6):1430-7
pubmed: 9641172
J Clin Endocrinol Metab. 2004 Aug;89(8):4010-7
pubmed: 15292342
Am J Physiol Renal Physiol. 2018 Apr 1;314(4):F667-F674
pubmed: 29357443
J Diabetes Res. 2016;2016:4626382
pubmed: 27247948
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
Kidney Int. 2005 May;67(5):1684-91
pubmed: 15840014
Dialogues Clin Neurosci. 2016 Dec;18(4):351-352
pubmed: 28179806
Diabetes Metab Syndr. 2020 May - Jun;14(3):181-187
pubmed: 32142999
Am J Physiol Renal Physiol. 2005 Feb;288(2):F399-405
pubmed: 15454392
Diabetes Care. 2018 May;41(5):963-970
pubmed: 29475843
Kidney Int. 2009 Jun;75(11):1194-1201
pubmed: 19279558
Nephrol Dial Transplant. 2006 Jan;21(1):16-20
pubmed: 16280370
Diabetes Care. 2006 Feb;29(2):312-6
pubmed: 16443879
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Kidney Int. 1994 Oct;46(4):1192-8
pubmed: 7861716
Am J Physiol Renal Physiol. 2016 Mar 9;310(10):F945-F957
pubmed: 26962103
Am J Physiol Cell Physiol. 2008 Aug;295(2):C475-89
pubmed: 18524944
J Am Soc Nephrol. 2010 Apr;21(4):556-63
pubmed: 20167701
Endocrine. 2017 Jan;55(1):66-76
pubmed: 27477292
Lancet. 2017 Oct 21;390(10105):1888-1917
pubmed: 28434650
Cardiovasc Diabetol. 2013 May 24;12:78
pubmed: 23705959
Am J Pathol. 2002 May;160(5):1877-85
pubmed: 12000739
Endocrine. 2005 Aug;27(3):301-5
pubmed: 16230788
Kidney Int. 2004 Oct;66(4):1596-605
pubmed: 15458456
Am J Physiol Renal Physiol. 2009 Apr;296(4):F680-8
pubmed: 19144692
J Am Soc Nephrol. 2000 Feb;11(2):319-329
pubmed: 10665939
BJOG. 2000 Aug;107(8):1017-21
pubmed: 10955435
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):854-861
pubmed: 31123181
Diabetes Care. 2003 Aug;26(8):2392-9
pubmed: 12882868